- ►endojournals.org JC Florez, KA Jablonski, MW Sun, N Bayley, … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Context: The common P12A polymorphism in PPARG (a target for thiazolidinedione
medications) has been consistently associated with type 2 diabetes. ...
Objective: We examined whether PPARG P12A affects progression from impaired ... Cited by 41 - Related articles - BL Direct - All 7 versions
JH Shon, YR Yoon, WS Hong, PM Nguyen, SS … - PHARMACOKINETICS AND DRUG DISPOSITION, 2005 - journals2005.pasteur.ac.ir Effect of itraconazole on the pharmacokinetics and pharmacodynamics of
fexofenadine in relation to the MDR1 genetic polymorphism Objective: Our
objective was to evaluate the effect of itraconazole, a P-glycoprotein ... Cited by 34 - Related articles - All 6 versions
- ►endojournals.org AH Xiang, RK Peters, SL Kjos, C Ochoa, A … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc We tested the effects of treatment with a thiazolidinedione drug on rates of
progression of carotid intima-media thickness (CIMT) and some putative
determinants of CIMT in young women at high risk for type 2 diabetes. A ... Cited by 35 - Related articles - All 7 versions
ES Kang, SY Park, HJ Kim, CS Kim, CW Ahn, … - Clinical pharmacology and therapeutics, 2005 - 134.68.189.85 Objective: The aim of this study was to examine the effects of the Pro12Ala
polymorphism of the peroxisome proliferator–activated receptor (PPAR) 2 gene
on the response to rosiglitazone in patients with type 2 diabetes mellitus. ... Cited by 32 - Related articles - View as HTML - All 8 versions
- ►nih.gov MI McCarthy, E Zeggini - Current Diabetes Reports, 2006 - Springer Introduction The growing prevalence of type 2 diabetes and obesity in societies
worldwide is widely recognized as among the greatest threats to global health in
the coming century [1]. Nevertheless, we remain far from a comprehensive ... Cited by 31 - Related articles - BL Direct - All 8 versions
- ►shouxi.net JK Wolford, KA Yeatts, SK Dhanjal, MH … - Diabetes, 2005 - Am Diabetes Assoc Thiazolidinediones (TZDs) are peroxisome proliferator–activated receptor-γ
(PPARG) agonists used to treat type 2 diabetes. TZDs can also be used to reduce
rates of type 2 diabetes in at-risk individuals. However, a large fraction ... Cited by 31 - Related articles - BL Direct - All 5 versions
SM Twigg, MC Kamp, TM Davis, EK Neylon, JR … - Medical Journal of Australia, 2007 - mja.com.au Definitions In 2002, the American Diabetes Association and the United States
Department of Health and Human Services2 defined prediabetes as the condition in
which blood glucose levels are elevated above the normal range but do not ... Cited by 15 - Related articles - View as HTML - BL Direct - All 11 versions
LK Chen, MH Lin, ZJ Chen, SJ Hwang, ST … - Diabetes research and clinical practice, 2006 - Elsevier Impaired fasting glucose (IFG), a newly defined category of glycemic metabolism,
has gained extensive attentions after the introduction of the diagnostic
criteria of diabetes mellitus (DM) by the American Diabetes Association. To ... Cited by 14 - Related articles - All 8 versions
L Li, L Cheng, R Nsenga, M He, T Wu - Clinical Cardiology, 2006 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 11 - Related articles - BL Direct - All 3 versions
H Koshiyama, S Honjo, Y Hamamoto, H Ikeda … - Medical hypotheses, 2006 - Elsevier There have been increasing evidences that atherosclerosis is not the result of
diabetes mellitus, but that both type 2 diabetes mellitus and atherosclerosis
may share common pathogenesis, as Stern proposed as 'common soil' ... Cited by 9 - Related articles - All 29 versions
